$BMY (-1,79 %) | Bristol-Myers Squibb Q2 earning highlights:

• EPS: $2.07 (estimate $1.64)
• Revenue: $12.2 billion (estimate $11.52 billion)

Raised Guidance:

• Q3 2024 earnings per share: $0.60 to $0.90 (estimate $0.51)
• Earnings per share in financial year 2024: $ 0.60 to $ (previously $ 0.40 to $ 0.70)

Best-selling drugs:

• Eliquis: $3.4 billion, up 7% from the previous year
• Opdivo: 2.4 billion US dollars, an increase of 11 % compared to the previous year
• Reblozyl: USD 425 million, an increase of 82% compared to the previous year
• Camzyos: USD 139 million, more than three times the previous year's figure

Other key figures:

• Adjusted gross margin: 75.6
• Net profit: $ 1.68 billion, a decrease from $ 2.07 billion in the previous year
• EBIT: $ 4.04 billion, compared to $ 4.99 billion in the previous year
• Free cash flow: $ 1.63 billion, a decrease from $ 3.36 billion in the previous year

Strategic developments:

• Phase 3 trial: cendakimab in patients with eosinophilic esophagitis met both primary endpoints
• Approvals: US approval of Breyanzi for follicular and mantle cell lymphoma, various international approvals for other drugs

CEO's comment:

• "Our second quarter results reflect progress in executing our strategy to focus BMS on long-term, sustainable growth," said Dr. Christopher Boerner, Chairman and CEO.